New drug trial targets Tough-to-Treat lymphoma
NCT ID NCT07332507
Summary
This early-phase study aims to find the safest and most effective dose of an experimental drug called teclistamab for adults with plasmablastic lymphoma that has returned or hasn't responded to previous treatments. The drug works by helping the body's immune T-cells recognize and attack cancer cells. Researchers will enroll about 30 patients to test safety, side effects, and whether the treatment can shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY PLASMABLASTIC LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.